Send to

Choose Destination
Respir Med Case Rep. 2017 Aug 29;22:197-202. doi: 10.1016/j.rmcr.2017.08.017. eCollection 2017.

Immunotherapy "Shock" a case series of PD-L1 100% and pembrolizumab first-line treatment.

Author information

Pulmonary-Oncology Unit, "Theageneio" Anticancer Hospital, Thessaloniki, Greece.
Private Pathology Center, "Microdiagnostics", Thessaloniki, Greece.
Department of Respiratory and Critical Care Medicine, Shanghai Hospital, Second Military Medical University, Shanghai, China.
Division of Pulmonology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Alexandra Hospital, Athens, Greece.
Surgery Department, "Interbalkan" European Medical Center, Thessaloniki, Greece.
Thoracic Surgery Department, "Theageneio" Anticancer Hospital, Thessaloniki, Greece.
2nd Pulmonary Department, "Sotiria" Hospital of Chest Diseases, Athens, Greece.
Private Scientigraphy Department, "Bioiatriki", Thessaloniki, Greece.
Sana Clinic Group Franken, Department of Cardiology/Pulmonology/Intensive Care/Nephrology, "Hof" Clinics, University of Erlangen, Hof, Germany.


In this decade a "bloom" of novel therapies has been observed for non-small cell lung cancer. We have new tools for the diagnosis of lung cancer and also we can re-biospy easier than before in different lesions and obtain tissue samples in order to investigate whether a patient can receive new targeted therapies. Immunotherapy has been well established previously for other forms of cancer, and nowadays it is also available for lung cancer. There are two immunotherapies for now nivolumab and pembrolizumab which can be administered as second line treatment, the second can also be administered as first-line if there is a programmed death-ligand 1 ≥50% expression.


Adenocarcinoma; Immunotherapy; Lung cancer; Nivolumab; Pembrolizumab; Programmed death-ligand

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center